Literature DB >> 33044680

Prognostic factors for patients with heparin-induced thrombocytopenia: a systematic review.

Giorgia Colarossi1, Heike Schnöring1, Andromahi Trivellas2, Marcel Betsch3, Nima Hatam1, Jörg Eschweiler4, Markus Tingart4, Filippo Migliorini5.   

Abstract

Background  Little is known with regards to the prognostic factors for patients with suspected or diagnosed Heparin-Induced Thromobocytopenia (HIT). The role of patient and therapy characteristics may play a role in predicting the outcome. Aim of the review To investigate the role of patient and therapy characteristics as potential prognostic factors for HIT-related complications (haemorrhagic and thromboembolic events), and mortality. Method The present systematic review was conducted according to the PRISMA statement. In September 2020, the main online databases were accessed: Pubmed, EMBASE, Scopus, Google Scholar. All the clinical trials concerning the management of patients with suspected or confirmed HIT were eligible. Studies evaluating the use of oral anticoagulants (e.g. vitamin K antagonists, Apixaban) were not considered, along with those comparing the use of heparin. For pairwise correlation, the Pearson Product-Moment Correlation Coefficient (r) was used. The final effect was evaluated according to the Cauchy-Schwarz inequality.Results Data from 33 clinical studies (4338 patients) were retrieved. The overall mean age was 62.3 ± 6.6 years old. Patients with HIT-related thromboembolism at the moment of diagnosis were associated with greater rate of haemorrhages (P > 0.0001), thromboembolism (P > 0.0001) and mortality (P = 0.001). Patients with more comorbidities at diagnosis were associated with a greater risk of haemorrhages (P = 0.07), thromboembolism (P = 0.002) and mortality (P = 0.002). Patients with longer duration of the therapy were associated with lower rate of mortality (P = 0.04). ConclusionsPatient comorbidities, presence of HIT-related thromboembolism on admission and shorter anticoagulant therapy were found to be negative prognostic factors. Thrombocythemia on admission, patients age and gender did not influence the overall outcome.

Entities:  

Keywords:  HIT; Heparin-induced thrombocytopenia; Prognostic factors; Systematic review

Mesh:

Substances:

Year:  2020        PMID: 33044680     DOI: 10.1007/s11096-020-01166-2

Source DB:  PubMed          Journal:  Int J Clin Pharm


  47 in total

1.  Temporal aspects of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; J G Kelton
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

Review 2.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

Review 3.  Heparin-induced thrombocytopenia (an overview).

Authors:  H L Daneschvar; H Daw
Journal:  Int J Clin Pract       Date:  2006-07-12       Impact factor: 2.503

Review 4.  Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  Adam Cuker; Phyllis A Gimotty; Mark A Crowther; Theodore E Warkentin
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

Review 5.  Heparin-induced thrombocytopaenia.

Authors:  Mark Prince; Tim Wenham
Journal:  Postgrad Med J       Date:  2018-08-20       Impact factor: 2.401

6.  Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization.

Authors:  O Iqbal; M Tobu; S Aziz; M Gerdisch; M Da Valle; M Demir; D A Hoppensteadt; S Ahmad; J M Walenga; J Fareed
Journal:  J Card Surg       Date:  2005 Jan-Feb       Impact factor: 1.620

Review 7.  An overview of heparin-induced thrombocytopenia.

Authors:  Jennifer L Donovan; Maichi T Tran; Abir O Kanaan
Journal:  J Pharm Pract       Date:  2010-04-13

8.  Incidence and Outcomes of Heparin-Induced Thrombocytopenia in Patients Undergoing Vascular Surgery.

Authors:  Rabail Chaudhry; Robert Wegner; John F Zaki; Greesha Pednekar; Alex Tse; Naveen Kukreja; Navneet Grewal; George W Williams
Journal:  J Cardiothorac Vasc Anesth       Date:  2017-05-17       Impact factor: 2.628

9.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

Review 10.  Heparin-induced Thrombocytopenia: Pathophysiology, Diagnosis and Management.

Authors:  Vasileios Patriarcheas; Antonios Pikoulas; Minas Kostis; Andriani Charpidou; Evangelos Dimakakos
Journal:  Cureus       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.